Reyedar is a technology company.
Reyedar has raised $3.0M across 1 funding round.
Reyedar has raised $3.0M in total across 1 funding round.
Reyedar has raised $3.0M in total across 1 funding round.
Reyedar's investors include Cottonwood Technology Fund.
Reyedar is a deeptech startup founded in 2020 that develops medical devices combining eye-tracking technology and AI for non-invasive, rapid screening of visual impairments like glaucoma and neurodegenerative diseases such as Parkinson's and multiple sclerosis.[1][2][3][4] Its flagship product, SONDA (Standardized Oculomotor Neuro-ophthalmic Disorders Assessment), uses AI-powered infrared glasses to measure eye movements in under 5 minutes, analyzing data via patented deep learning algorithms to deliver clinical insights on visual field sensitivity and disease risk.[2][3][4] Serving opticians, optometry centers, hospitals, private clinics, and research facilities, Reyedar reduces testing times and costs while enabling early detection to improve outcomes and ease healthcare burdens.[1][2][5] The company has raised $3.27M in seed funding, led by Cottonwood Technology Fund, and operates from Groningen, Netherlands, after rebranding from Reperio Medtech.[1][3][4]
Reyedar emerged as a spin-off from the ophthalmology department of the University Medical Center Groningen, founded in 2020 by Dr. Alessandro Grillini, who serves as CEO.[3][4] Grillini, leveraging research expertise, co-developed the core technology to address limitations in invasive, time-consuming screenings for age-related degenerative diseases amid a growing aging population.[3][4] Pivotal early validation came from positive results published in *Frontiers in Neurology*, affirming SONDA's efficacy, while a 2023 €3M seed round—led by Cottonwood Technology Fund with NOM, Pupil Labs, Uneti Ventures, and Blue Sparrows MedTech Fund—accelerated commercialization.[1][3][4] Investors praised the team's entrepreneurial mindset and global network, with CEO Jurryt Vellinga (noted in testimonials) highlighting Cottonwood's role in securing early corporate customers.[1]
Reyedar rides the wave of AI-enhanced medtech and precision diagnostics, capitalizing on an aging global population driving demand for scalable screening of glaucoma, Parkinson's, and MS—diseases straining healthcare systems with outdated, unreliable tests.[3][4] Its timing aligns with advances in wearable sensors and deep learning, enabling accessible "windows to the brain" via eye movements, a trend amplified by post-pandemic telehealth and cost pressures.[1][2][5] Market forces like rising neurodegenerative cases and investor interest in deeptech health (e.g., Cottonwood's focus on impact) favor Reyedar, as it influences the ecosystem by democratizing early detection in primary care settings, potentially lowering costs and improving outcomes for millions.[1][3][4]
Reyedar is poised to launch its first eye care product post-funding, expanding SONDA's scope to broader neurological and cognitive applications while growing its team for commercialization.[3][4] Trends like AI-medtech convergence, wearable diagnostics, and value-based healthcare will propel it, especially as regulatory nods and clinical adoption build on its research pedigree.[1][4] Its influence may evolve from niche screening to a platform standard, enhancing healthier aging—if it scales manufacturing and partnerships amid competitive diagnostics landscapes. This positions Reyedar as a prime example of research-driven entrepreneurship tackling healthcare's early-detection walls.[1][3]
Reyedar has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $3.0M Seed | Cottonwood Technology Fund |